Worth Venture Partners LLC trimmed its stake in SPDR S&P Biotech (NYSEARCA:XBI) by 26.0% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 8,318 shares of the exchange traded fund’s stock after selling 2,916 shares during the period. Worth Venture Partners LLC’s holdings in SPDR S&P Biotech were worth $720,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of the company. Wechter Feldman Wealth Management Inc. lifted its stake in shares of SPDR S&P Biotech by 0.4% in the 2nd quarter. Wechter Feldman Wealth Management Inc. now owns 3,172 shares of the exchange traded fund’s stock valued at $245,000 after purchasing an additional 12 shares during the last quarter. Newman Dignan & Sheerar Inc. lifted its stake in shares of SPDR S&P Biotech by 0.6% in the 2nd quarter. Newman Dignan & Sheerar Inc. now owns 8,260 shares of the exchange traded fund’s stock valued at $638,000 after purchasing an additional 50 shares during the last quarter. Willingdon Wealth Management lifted its stake in shares of SPDR S&P Biotech by 1.8% in the 2nd quarter. Willingdon Wealth Management now owns 6,541 shares of the exchange traded fund’s stock valued at $505,000 after purchasing an additional 118 shares during the last quarter. Bank of New York Mellon Corp lifted its stake in shares of SPDR S&P Biotech by 1.0% in the 2nd quarter. Bank of New York Mellon Corp now owns 19,274 shares of the exchange traded fund’s stock valued at $1,488,000 after purchasing an additional 197 shares during the last quarter. Finally, Vestor Capital LLC lifted its stake in shares of SPDR S&P Biotech by 0.5% in the 2nd quarter. Vestor Capital LLC now owns 38,663 shares of the exchange traded fund’s stock valued at $2,984,000 after purchasing an additional 208 shares during the last quarter.

COPYRIGHT VIOLATION NOTICE: “Worth Venture Partners LLC Reduces Position in SPDR S&P Biotech (XBI)” was originally published by TheOlympiaReport and is owned by of TheOlympiaReport. If you are reading this article on another site, it was copied illegally and republished in violation of US and international copyright & trademark laws. The correct version of this article can be read at https://theolympiareport.com/2017/11/14/worth-venture-partners-llc-reduces-position-in-spdr-sp-biotech-xbi.html.

SPDR S&P Biotech (NYSEARCA XBI) traded down $1.09 during trading hours on Tuesday, hitting $81.68. The stock had a trading volume of 3,542,500 shares, compared to its average volume of 4,216,511. SPDR S&P Biotech has a 1-year low of $58.66 and a 1-year high of $88.98.

SPDR S&P Biotech Company Profile

SPDR S&P Biotech ETF (the Fund) seeks to closely match the returns and characteristics of the S&P Biotechnology Select Industry Index. The S&P Biotechnology Select Industry Index represents the biotechnology sub-industry portion of the S&P Total Markets Index. The S&P TMI tracks all the United States common stocks listed on the New York Stock Exchange, American Stock Exchange, National Association of Securities Dealers Automated Quotation (NASDAQ) National Market and NASDAQ Small Cap exchanges.

Institutional Ownership by Quarter for SPDR S&P Biotech (NYSEARCA:XBI)

Receive News & Ratings for SPDR S&P Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SPDR S&P Biotech and related companies with Analyst Ratings Network's FREE daily email newsletter.